Synopsis
Synopsis
0
VMF
0
FDF
0
Stock Recap #PipelineProspector


1. Galantamin
2. Galantamine
3. Galanthamine
4. Galanthamine Hydrobromide
5. Lycoremine
6. Nivalin
7. Nivaline
8. Razadyne
9. Reminyl
1. Galanthamine Hydrobromide
2. 1953-04-4
3. Reminyl
4. Nivalin
5. Nivaline
6. Razadyne
7. Lycoremine Hydrobromide
8. Jilkon Hydrobromide
9. Galanthamine (hydrobromide)
10. Galanthamine Hbr
11. Tamilin
12. 193146-85-9
13. Mj4ptd2vvw
14. 5n4sa4kqx9
15. (-)-galantamine Hydrobromide
16. (+/-)-galantamine Hydrobromide
17. (+/-)-galanthamine Hydrobromide
18. Galantamine Hydrobromide (racemic)
19. Galantamine Hydrobromide, (+/-)-
20. (1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol;hydrobromide
21. (4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol Hydrobromide
22. Razadyne Er
23. Reminyl (tn)
24. (1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azoniatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol;bromide
25. (4as,6r,8as)-3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6h-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol Hydrobromide
26. Galanthaminehydrobromide
27. 1953-04-4 (hbr); 1953-04-4 (free Base).
28. (1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0^{1,12}.0^{6,17}]heptadeca-6(17),7,9,15-tetraen-14-ol Hydrobromide
29. (4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol Hydrobromide
30. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hydrobromide (1:1), (4ar,6s,8ar)-rel-
31. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hydrobromide (1:1), (4as,6r,8as)-
32. Smr000449267
33. Sr-01000597844
34. Nivaline (pharmaceutical)
35. C17h22brno3
36. Anti-alzheimer
37. Sr-05000001783
38. Nivalin;razadyne
39. Galantamine Hydrobromide [usan]
40. Reminyl Xl
41. Jilcon Hydrobromide
42. Razadyne (tn)
43. Prestwick_236
44. Einecs 217-780-5
45. Galanthamine Hydrobromide From Lycoris Sp.
46. Mfcd00067672
47. Unii-mj4ptd2vvw
48. Unii-5n4sa4kqx9
49. 1953-04-4 Unlabeled
50. Chembl1555
51. Galanthamine-d3 Hydrobromide
52. Mls000758283
53. Mls001401401
54. Galanthamine Hydrobromide,(s)
55. Schembl177993
56. Spectrum1501202
57. Hms1569f18
58. Hms1921p21
59. Hy-a0009
60. Galantamine Hydrobromide (jan/usp)
61. Ac-469
62. Ccg-38829
63. Galantamine Hydrobromide [mi]
64. Galantamine Hydrobromide [usan:usp]
65. S1339
66. Galantamine Hydrobromide [jan]
67. Galanthamine-o-methyl-d3 Hydrobromide
68. Akos007930166
69. Akos015960209
70. Cs-0378
71. Fd10095
72. Galantamine Hydrobromide [hsdb]
73. Nc00061
74. Galantamine Hydrobromide [mart.]
75. Galantamine Hydrobromide [vandf]
76. Galantamine Hydrobromide [usp-rs]
77. Galantamine Hydrobromide [who-dd]
78. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hydrobromide, (4as,6r,8as)-
79. As-12155
80. Gp-37267
81. G0293
82. Galantamine Hydrobromide [orange Book]
83. D02173
84. Galantamine Hydrobromide [ep Monograph]
85. Galantamine Hydrobromide [usp Monograph]
86. Galantamine Hydrobromide Racemic [usp-rs]
87. 953g044
88. A866857
89. A903748
90. R-113675
91. Sr-01000597844-1
92. Sr-01000597844-5
93. Sr-05000001783-3
94. Q47495772
95. Z1558572528
96. Galanthamine Hydrobromide From Lycoris Sp., >=94% (tlc)
97. (4as,6r,8as)-3-methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4ah-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol Hydrobromide
98. (4as,6r,8as)-3-methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4ah-benzo[2,3]benzofuro[4,3-cd]azepin-6-olhydrobromide
99. (4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, Hydrobromide
100. (4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-d3-11-methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol Hydrobromide
101. 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol Hydrobromide
102. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hbr (1:1), (4as,6r,8as)-
103. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hbr, (4as,6r,8as)-
104. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hydrobromide, (4a.alpha.,6.beta.,8ar*)-
105. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Hydrobromide, (4aalpha,6beta,8ar*)-
1. Galantamine
2. Galanthamine Hydrobromide
3. Lycoremin
4. Lycoremine
5. Nivalin
6. Razadyne
7. Reminyl
8. Galanthamine
| Molecular Weight | 368.3 g/mol |
|---|---|
| Molecular Formula | C17H22BrNO3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 1 |
| Exact Mass | 367.07831 g/mol |
| Monoisotopic Mass | 367.07831 g/mol |
| Topological Polar Surface Area | 41.9 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 440 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Galantamine hydrobromide |
| PubMed Health | Galantamine (By mouth) |
| Drug Classes | Central Nervous System Agent |
| Drug Label | Galantamine hydrobromide is a reversible, competitive acetylcholinesterase inhibitor. Galantamine hydrobromide is known chemically as (4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro [3a,3,2-ef][2]benzazepin-6-ol hydrobromide.... |
| Active Ingredient | Galantamine hydrobromide |
| Dosage Form | Tablet; Capsule, extended release; Solution |
| Route | oral; Oral |
| Strength | eq 4mg base; 8mg; eq 12mg base; 4mg; 4mg/ml; 12mg; eq 16mg base; eq 24mg base; eq 8mg base |
| Market Status | Tentative Approval; Prescription |
| Company | Ranbaxy; Apotex; Aurobindo Pharma; Sun Pharm Inds; Sandoz; Sun Pharma Global; Roxane; Watson Labs; Teva Pharms; Zydus Pharms Usa; Dr Reddys Labs; Mylan; Impax Labs; Barr |
| 2 of 4 | |
|---|---|
| Drug Name | Razadyne |
| Drug Label | RAZADYNE ER/RAZADYNE (galantamine hydrobromide) is galantamine hydrobromide, a reversible, competitive acetylcholinesterase inhibitor. Galantamine hydrobromide is known chemically as (4aS ,6R,8aS )-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H... |
| Active Ingredient | Galantamine hydrobromide |
| Dosage Form | Tablet; Solution |
| Route | Oral |
| Strength | eq 4mg base; eq 12mg base; 4mg/ml; eq 8mg base |
| Market Status | Prescription |
| Company | Janssen Pharms |
| 3 of 4 | |
|---|---|
| Drug Name | Galantamine hydrobromide |
| PubMed Health | Galantamine (By mouth) |
| Drug Classes | Central Nervous System Agent |
| Drug Label | Galantamine hydrobromide is a reversible, competitive acetylcholinesterase inhibitor. Galantamine hydrobromide is known chemically as (4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro [3a,3,2-ef][2]benzazepin-6-ol hydrobromide.... |
| Active Ingredient | Galantamine hydrobromide |
| Dosage Form | Tablet; Capsule, extended release; Solution |
| Route | oral; Oral |
| Strength | eq 4mg base; 8mg; eq 12mg base; 4mg; 4mg/ml; 12mg; eq 16mg base; eq 24mg base; eq 8mg base |
| Market Status | Tentative Approval; Prescription |
| Company | Ranbaxy; Apotex; Aurobindo Pharma; Sun Pharm Inds; Sandoz; Sun Pharma Global; Roxane; Watson Labs; Teva Pharms; Zydus Pharms Usa; Dr Reddys Labs; Mylan; Impax Labs; Barr |
| 4 of 4 | |
|---|---|
| Drug Name | Razadyne |
| Drug Label | RAZADYNE ER/RAZADYNE (galantamine hydrobromide) is galantamine hydrobromide, a reversible, competitive acetylcholinesterase inhibitor. Galantamine hydrobromide is known chemically as (4aS ,6R,8aS )-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H... |
| Active Ingredient | Galantamine hydrobromide |
| Dosage Form | Tablet; Solution |
| Route | Oral |
| Strength | eq 4mg base; eq 12mg base; 4mg/ml; eq 8mg base |
| Market Status | Prescription |
| Company | Janssen Pharms |
Nootropic Agents
Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)
Cholinesterase Inhibitors
Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)
Parasympathomimetics
Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)
Indena - Advancing botanical science with a century of innovation, quality, and trusted global expertise.
Indena - Advancing botanical science with a century of innovation, quality, and trusted global expertise.
Galantamine Hydrobromide, Isolated From Natural ...
Certificate Number : R1-CEP 2011-288 - Rev 01
Status : Valid
Issue Date : 2020-11-19
Type : Chemical
Substance Number : 2366
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Galantamine Hydrobromide, Produced By A Syntheti...
Certificate Number : CEP 2009-316 - Rev 03
Status : Valid
Issue Date : 2024-10-30
Type : Chemical
Substance Number : 2366

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Galantamine Hydrobromide, Produced By A Syntheti...
Certificate Number : R1-CEP 2012-248 - Rev 01
Status : Valid
Issue Date : 2021-11-19
Type : Chemical
Substance Number : 2366

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Galantamine Hydrobromide, Produced By A Syntheti...
Certificate Number : CEP 2011-123 - Rev 03
Status : Valid
Issue Date : 2026-01-16
Type : Chemical
Substance Number : 2366

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Galantamine Hydrobromide, Produced By A Syntheti...
Certificate Number : CEP 2023-389 - Rev 00
Status : Valid
Issue Date : 2024-06-19
Type : Chemical
Substance Number : 2366

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Galantamine Hydrobromide, Produced By A Syntheti...
Certificate Number : R1-CEP 2012-328 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2019-03-07
Type : Chemical
Substance Number : 2366

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Galantamine Hydrobromide, Produced By A Syntheti...
Certificate Number : CEP 2011-011 - Rev 02
Status : Valid
Issue Date : 2024-10-21
Type : Chemical
Substance Number : 2366

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Galantamine Hydrobromide, Isolated From Natural ...
Certificate Number : CEP 2011-053 - Rev 03
Status : Valid
Issue Date : 2025-01-13
Type : Chemical
Substance Number : 2366

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF

Galantamine Hydrobromide, Isolated From Natural ...
Certificate Number : CEP 2024-450 - Rev 00
Status : Valid
Issue Date : 2026-03-19
Type : Chemical
Substance Number : 2366

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] Details:
Galantamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Galantamine Hydrobromide,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 13, 2011
Lead Product(s) : Galantamine Hydrobromide,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Galantamine Bioequivalence Study of Dr. Reddy's Under Fasting Condition
Details : Galantamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 13, 2011
Details:
Reminyl (Galantamine) is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Feeding and Eating Disorders.
Lead Product(s): Galantamine Hydrobromide,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Reminyl
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 13, 2011
Lead Product(s) : Galantamine Hydrobromide,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition
Details : Reminyl (Galantamine) is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Feeding and Eating Disorders.
Product Name : Reminyl
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 13, 2011
Details:
Galantamine HBr is a Miscellaneous drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Spinal Cord Injuries.
Lead Product(s): Galantamine Hydrobromide,Inapplicable
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Bronx Veterans Medical Research Foundation, Inc | Kessler Institute for Rehabilitation
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 04, 2026

Lead Product(s) : Galantamine Hydrobromide,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Bronx Veterans Medical Research Foundation, Inc | Kessler Institute for Rehabilitation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Galantamine HBr is a Miscellaneous drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Spinal Cord Injuries.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 04, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Galantamine HBr, a miscellaneous product targeting acetylcholinesterase, shows promise in treating sarcopenia.
Lead Product(s): Galantamine Hydrobromide,Metformin
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 01, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Galantamine Hydrobromide,Metformin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Rejuvenate Biomed Finishes Phase 2 Trial of RJx-01 in COPD-Induced Sarcopenia
Details : Galantamine HBr, a miscellaneous product targeting acetylcholinesterase, shows promise in treating sarcopenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 01, 2026

Details:
Mononuclear Cell is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Alzheimer Disease.
Lead Product(s): Mononuclear Cell,Donepezil,Rivastigmine,Galantamine Hydrobromide
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Cell & Gene Therapy
Sponsor: Shandong Qilu Stem Cell Engineering Co., Ltd.
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 06, 2025

Lead Product(s) : Mononuclear Cell,Donepezil,Rivastigmine,Galantamine Hydrobromide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Shandong Qilu Stem Cell Engineering Co., Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease
Details : Mononuclear Cell is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 06, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
RJx-01 is a combination of galantamine and metformin, works by inhibiting AChE and acting as an allosteric modulator of nAChRs, being investigated for COPD-related muscle weakness.
Lead Product(s): Galantamine Hydrobromide,Metformin
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: National Institute for Health and Care Research
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Galantamine Hydrobromide,Metformin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : National Institute for Health and Care Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Rejuvenate Doses First Patient in Phase 2 Trial on COPD Muscle Weakness & Sarcopenia
Details : RJx-01 is a combination of galantamine and metformin, works by inhibiting AChE and acting as an allosteric modulator of nAChRs, being investigated for COPD-related muscle weakness.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Galantamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Lead Product(s): Galantamine Hydrobromide,Striatin
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 16, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Galantamine Hydrobromide,Striatin
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Supplementation of Galatonol 300 mg / Striatin 30 mg in Postpartum Lactating Mothers
Details : Galantamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Essential Pharma has acquired rights to Reminyl (galantamine), a cholinesterase inhibitor, for the EEA, Thailand, South Korea, and other markets, excluding the UK and Japan.
Lead Product(s): Galantamine Hydrobromide,Inapplicable
Therapeutic Area: Neurology Brand Name: Reminyl
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Essential Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 17, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Galantamine Hydrobromide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Essential Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Essential Pharma Acquires Reminyl® (galantamine hydrobromide) Capsules
Details : Essential Pharma has acquired rights to Reminyl (galantamine), a cholinesterase inhibitor, for the EEA, Thailand, South Korea, and other markets, excluding the UK and Japan.
Product Name : Reminyl
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 17, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
RJx-01, a novel combination drug comprising galantamine and metformin, demonstrated positive results in 42 elderly male subjects with disuse-induced muscle atrophy.
Lead Product(s): Galantamine Hydrobromide,Metformin
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 04, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Galantamine Hydrobromide,Metformin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RJx-01, a novel combination drug comprising galantamine and metformin, demonstrated positive results in 42 elderly male subjects with disuse-induced muscle atrophy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
RJx-01 is a novel combination of known drugs, there are already extensive safety data available for the constituent compounds. Results will be based on a combination of classic and hi-tech assessment techniques, including data from wearable health tech devices.
Lead Product(s): Galantamine Hydrobromide,Inapplicable
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 29, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Galantamine Hydrobromide,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Rejuvenate Biomed Started a Groundbreaking Clinical Trial and Expands for Future Growth
Details : RJx-01 is a novel combination of known drugs, there are already extensive safety data available for the constituent compounds. Results will be based on a combination of classic and hi-tech assessment techniques, including data from wearable health tech d...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 29, 2022

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CAS Number : 510-77-0
End Use API : Galantamine Hydrobromide
About The Company : Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
62
PharmaCompass offers a list of Galantamine Hydrobromide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Galantamine Hydrobromide manufacturer or Galantamine Hydrobromide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Galantamine Hydrobromide manufacturer or Galantamine Hydrobromide supplier.
A Galanthamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Galanthamine, including repackagers and relabelers. The FDA regulates Galanthamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Galanthamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Galanthamine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Galanthamine supplier is an individual or a company that provides Galanthamine active pharmaceutical ingredient (API) or Galanthamine finished formulations upon request. The Galanthamine suppliers may include Galanthamine API manufacturers, exporters, distributors and traders.
click here to find a list of Galanthamine suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Galanthamine DMF (Drug Master File) is a document detailing the whole manufacturing process of Galanthamine active pharmaceutical ingredient (API) in detail. Different forms of Galanthamine DMFs exist exist since differing nations have different regulations, such as Galanthamine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Galanthamine DMF submitted to regulatory agencies in the US is known as a USDMF. Galanthamine USDMF includes data on Galanthamine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Galanthamine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Galanthamine suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Galanthamine Drug Master File in Japan (Galanthamine JDMF) empowers Galanthamine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Galanthamine JDMF during the approval evaluation for pharmaceutical products. At the time of Galanthamine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Galanthamine suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Galanthamine Drug Master File in Korea (Galanthamine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Galanthamine. The MFDS reviews the Galanthamine KDMF as part of the drug registration process and uses the information provided in the Galanthamine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Galanthamine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Galanthamine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Galanthamine suppliers with KDMF on PharmaCompass.
A Galanthamine CEP of the European Pharmacopoeia monograph is often referred to as a Galanthamine Certificate of Suitability (COS). The purpose of a Galanthamine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Galanthamine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Galanthamine to their clients by showing that a Galanthamine CEP has been issued for it. The manufacturer submits a Galanthamine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Galanthamine CEP holder for the record. Additionally, the data presented in the Galanthamine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Galanthamine DMF.
A Galanthamine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Galanthamine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Galanthamine suppliers with CEP (COS) on PharmaCompass.
A Galanthamine written confirmation (Galanthamine WC) is an official document issued by a regulatory agency to a Galanthamine manufacturer, verifying that the manufacturing facility of a Galanthamine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Galanthamine APIs or Galanthamine finished pharmaceutical products to another nation, regulatory agencies frequently require a Galanthamine WC (written confirmation) as part of the regulatory process.
click here to find a list of Galanthamine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Galanthamine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Galanthamine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Galanthamine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Galanthamine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Galanthamine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Galanthamine suppliers with NDC on PharmaCompass.
Galanthamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Galanthamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Galanthamine GMP manufacturer or Galanthamine GMP API supplier for your needs.
A Galanthamine CoA (Certificate of Analysis) is a formal document that attests to Galanthamine's compliance with Galanthamine specifications and serves as a tool for batch-level quality control.
Galanthamine CoA mostly includes findings from lab analyses of a specific batch. For each Galanthamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Galanthamine may be tested according to a variety of international standards, such as European Pharmacopoeia (Galanthamine EP), Galanthamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Galanthamine USP).